Wanbury (NSE: WANBURY) launches Berrysoft Baby skincare range across India as profit falls 76%

Wanbury Limited (NSE: WANBURY; BSE: 524212) has entered India’s paediatric dermatology segment through the launch of its Berrysoft Baby skincare range, expanding beyond its established pharmaceutical portfolio into products for infant cleansing and hygiene. The October 12, 2026 announcement confirms that its subsidiary, Wanbury Skin Health Limited, has launched four products across multiple states, with three additional skincare products under development. The expansion draws on Wanbury’s existing relationships with paediatricians while establishing new distribution and promotional opportunities among dermatologists. It comes at a challenging time for the Mumbai-based pharmaceutical company, which reported a 76% year-on-year decline in net profit to ₹3.2 crore in Q1 FY27 despite modest revenue growth. The commercial test is whether the new consumer-oriented dermatology portfolio can generate profitable sales without placing additional pressure on marketing expenditure and operating margins.

The initial Berrysoft Baby portfolio comprises Gentle Bathing Bar, Gentle Body Wash, Foam Shampoo and Syndet Handwash, with Moisturising Lotion, Diaper Rash Cream and Moisturising Cream planned for subsequent introduction. Wanbury Skin Health has obtained goods and services tax registrations in five states, including Maharashtra, Delhi and Karnataka, with three more registrations in progress. It has also secured carrying and forwarding agent drug licences in Mumbai, Jaipur, Patna and Ambala, while another four locations remain in the licensing pipeline. These arrangements provide an initial distribution foundation, although the company has not disclosed product pricing, sales targets, launch expenditure or the expected financial contribution from the new range.

Why is Wanbury targeting paediatric dermatology through its new Berrysoft Baby range?

Wanbury’s expansion into baby skincare represents an effort to extend its domestic branded formulations business into adjacent healthcare categories. The company already markets cough and cold products through relationships with paediatricians, providing an established professional network that could support awareness of its new skincare portfolio. By introducing infant cleansing and hygiene products through Wanbury Skin Health Limited, it aims to increase the range of products offered to healthcare professionals and strengthen its presence in paediatric care. However, existing relationships do not automatically guarantee product recommendations or consumer purchases.

The four launched products address routine cleansing needs rather than representing a portfolio of newly approved prescription medicines. Future additions, particularly diaper rash cream and moisturising products, could broaden the brand’s relevance across infant skincare routines, depending on their final formulations and approved claims. Wanbury has not published clinical evidence or detailed product specifications establishing comparative performance against competing brands. Its commercial proposition must therefore be assessed through distribution, product quality, pricing and customer adoption rather than unverified therapeutic advantages.

The launch also introduces a potentially different demand pattern from the company’s active pharmaceutical ingredients (API) business, where sales depend heavily on pharmaceutical manufacturers and international customers. Baby skincare products may generate recurring household purchases through retail and pharmacy channels, although purchase frequency and customer loyalty will determine the actual opportunity. A successful consumer-facing portfolio could diversify Wanbury’s revenue composition over time, but the present announcement contains no sales guidance or indication that the category will materially influence near-term earnings.

How important are Wanbury Skin Health’s five state registrations and distribution licences?

Wanbury Skin Health’s initial operational footprint includes GST registrations in five states, with Maharashtra, Delhi and Karnataka specifically identified. Another three state registrations are being pursued, potentially widening the company’s geographical presence once completed. Separately, the subsidiary has obtained carrying and forwarding agent drug licences in Mumbai, Jaipur, Patna and Ambala, with four more locations in the pipeline. These approvals and registrations establish part of the infrastructure required for commercial distribution, although they should not be interpreted as evidence of nationwide availability or confirmed retail penetration.

The distribution strategy appears designed to support an organised rollout rather than a simultaneous launch into every Indian market. Establishing regional supply arrangements could help the company manage inventory, product availability and relationships with pharmacies and other distribution partners. However, the number of registered states or licensed logistics locations does not establish how many retail outlets are currently stocking Berrysoft Baby products. Sales coverage will depend on the appointment of distributors, order generation and the development of a functioning supply chain.

The subsidiary also intends to build relationships with dermatologists alongside its existing paediatrician network. This could broaden its professional engagement as additional moisturising and skincare products reach the market. However, Wanbury has not disclosed a dedicated salesforce size, marketing budget or distribution agreement associated with the launch. Those details would provide a stronger indication of the resources being committed to the new business.

Can Berrysoft Baby improve Wanbury’s business mix after its sharp Q1 FY27 margin decline?

The launch follows a difficult first quarter for Wanbury’s existing operations. Revenue from operations increased just 1.5% year-on-year to ₹165.6 crore during Q1 FY27, compared with ₹163.2 crore a year earlier. EBITDA, including other income, fell approximately 33% to ₹16.6 crore, while the EBITDA margin contracted from 15.2% to 10%. Net profit declined from ₹13.5 crore to ₹3.2 crore, reflecting the effect of cost pressures on the company’s profitability.

Management attributed much of the deterioration to disruptions arising from the West Asia crisis, including delayed API export shipments and higher prices for solvents and other crude-oil-linked inputs. Gross margin declined from 54% in Q1 FY26 to 52.5% in Q1 FY27, while additional hiring for growth initiatives contributed to operating expenditure. The company indicated in August that it expected these pressures to ease and margins to recover from Q2 FY27 onward. That recovery remains management guidance until supported by subsequent financial results.

Berrysoft Baby could eventually provide another source of branded-product revenue, but there is insufficient evidence to conclude that the range will deliver higher margins than Wanbury’s existing businesses. Consumer skincare profitability depends on manufacturing costs, advertising expenditure, discounts, distribution margins and the ability to secure repeat purchases. New brands may also require upfront promotional investment before reaching meaningful sales volumes. Consequently, the product launch is better understood as a medium-term portfolio diversification initiative than an immediate solution to the company’s June-quarter profitability decline.

The scale of the existing business provides a useful perspective. With quarterly revenue of ₹165.6 crore, Wanbury would need substantial incremental sales for a new product range to alter consolidated growth significantly. A hypothetical ₹5 crore of quarterly revenue from Berrysoft Baby would represent roughly 3% of the June-quarter revenue base, before accounting for any effect on existing operations. That illustration is not company guidance, but it shows why disclosure of actual brand sales will matter more than the number of products introduced.

How does Wanbury’s pharmaceutical business support its diversification strategy?

Wanbury’s established pharmaceutical operations provide both commercial infrastructure and a financial foundation for expansion into skincare. Its API portfolio includes products such as Metformin, Sertraline, Tramadol, Diphenhydramine and Paroxetine, with exports reaching more than 50 countries. The company operates API manufacturing facilities at Tanuku in Andhra Pradesh and Patalganga in Maharashtra, alongside its domestic branded formulations business. These existing operations remain substantially more established than the newly launched Berrysoft Baby portfolio.

Recent regulatory developments have also strengthened parts of the API business. During Q1 FY27, Wanbury reported a successful Therapeutic Goods Administration inspection at Tanuku, with additional Australian API exports dependent on the associated GMP certification. Its Patalganga facility received the relevant inspection report and GMP certification following a South Korean regulatory inspection. The company also reported regulatory progress involving Rivaroxaban and US Food and Drug Administration drug master file reviews for other APIs, although those milestones should not be confused with final approval of every finished pharmaceutical product.

The company has separately refinanced ₹205 crore of borrowings through facilities involving Axis Finance Limited and Poonawalla Fincorp Limited. Management said the refinancing reduced its borrowing cost from approximately 12.5% to below 10% annually, with benefits expected from July 2026. Lower financing expenditure could support profitability, provided the revised borrowing terms and operating performance develop as anticipated. The skincare expansion is therefore occurring alongside efforts to improve the economics of Wanbury’s existing pharmaceutical operations.

What does WANBURY’s recent share-price performance suggest about investor sentiment?

Wanbury shares closed at ₹196.42 on October 9, 2026, approximately 1.14% above the previous session’s close. The stock remained around 45% below its reported 52-week high of ₹358.85, reflecting a substantial retreat from earlier trading levels. The October 12 Berrysoft Baby announcement followed that closing price, so the earlier movement cannot be attributed to the product launch. The stock’s recent weakness provides useful context, but it does not establish the market’s valuation of the new skincare business.

The investment case currently involves two different sources of potential improvement. The established API and formulations businesses could benefit from lower borrowing costs, stabilising input prices and stronger export execution, while Wanbury Skin Health may create incremental demand through its paediatric and dermatology products. The first set of opportunities is connected to existing revenue and disclosed financial performance, whereas the second remains at an early commercial stage. Treating both as equally mature earnings contributors would overstate the evidence available.

Investors will also need to distinguish increased product availability from actual commercial traction. The company’s October filing does not disclose distributor sales commitments, revenue forecasts or the expected contribution of Berrysoft Baby to consolidated profitability. A more favourable assessment of the diversification strategy would require recurring sales growth and evidence that customer acquisition costs are being absorbed without weakening margins. Until then, the launch provides a new operating catalyst but no quantified basis for revising earnings expectations.

What will determine whether Wanbury’s Berrysoft Baby expansion becomes commercially meaningful?

The immediate operational priorities are the completion of additional state registrations, expansion of carrying and forwarding arrangements, and introduction of the three products currently in the pipeline. These milestones could broaden the brand’s addressable customer base and give the company a more complete infant skincare offering. Progress will be more meaningful if accompanied by disclosure of pharmacy coverage, sales growth or repeat customer demand. Product launches alone do not demonstrate that a new category has achieved sustainable commercial scale.

Wanbury’s next financial results will also test management’s expectation of recovering margins and lower finance costs following its debt refinancing. Improved profitability in the existing business could provide greater financial flexibility to support the skincare rollout, while continued margin pressure would make disciplined marketing and distribution spending more important. The company has not disclosed a break-even target or investment timetable for Wanbury Skin Health.

Berrysoft Baby marks a clear extension of Wanbury’s domestic healthcare portfolio into paediatric skincare, supported by an initial multi-state distribution infrastructure and existing relationships with medical professionals. The strategy offers an opportunity to develop recurring branded-product revenue, but its financial importance remains unquantified. The most convincing evidence of success will be measurable brand sales, wider retail availability and sustained profitability alongside a recovery in Wanbury’s established pharmaceutical operations.

What are the key takeaways from Wanbury’s Berrysoft Baby launch?

• Wanbury Skin Health Limited launched Berrysoft Baby across multiple Indian states on October 12, 2026.
• Four infant cleansing and hygiene products are available, with three additional products planned.
• The subsidiary has GST registrations in five states and carrying and forwarding agent drug licences in four cities.
• Existing paediatrician relationships form an important part of the expansion strategy.
• The company plans to develop additional relationships with dermatologists.
• Wanbury’s Q1 FY27 revenue increased 1.5% to ₹165.6 crore, while net profit declined 76%.
• The new skincare range has no disclosed revenue target, investment budget or profitability timetable.
• Commercial progress will depend on distribution growth, product adoption, repeat purchases and operating margins.